Market research
BD5.F BioDelivery Sciences International, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 524M
- P/E ratio
- 6.8
- Analyst target
- 7.32
- Dividend yield
- 0.0%
- Beta
- 0.56
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 524M
- P/E ratio
- 6.8
- Analyst target
- 7.32
- Dividend yield
- 0.0%
- Beta
- 0.56
About
About BioDelivery Sciences International, Inc
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BD5.F discussion.
5 years, 5 months ago
BioDelivery Sciences International, Inc is currently in a long term downtrend where the price is trading 3.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
BioDelivery Sciences International, Inc's total revenue rose by 33.3% to $42M since the same quarter in the previous year.
Its net income has increased by 1565.1% to $10M since the same quarter in the previous year.
Finally, its free cash flow fell by 35.0% to $11M since the same quarter in the previous year.
Based on the above factors, BioDelivery Sciences International, Inc gets an overall score of 3/5.